Literature DB >> 16168238

Chemoprophylaxis of colon cancer.

Bandaru S Reddy1, Chinthalapally V Rao.   

Abstract

There is convincing evidence that chemoprevention has the potential to be a major component of colorectal cancer control. Experimental, epidemiologic, and clinical studies provide evidence that nonsteroidal anti-inflammatory drugs (NSAIDs), particularly the selective cyclooxygenase (COX)-2 inhibitors, including celecoxib and several phytochemicals, act as anticancer agents. However, several of these chemopreventive agents induce side effects at effective high dose levels. Low doses of atorvastatin and aspirin, or atorvastatin and celecoxib, or piroxicam and difluoromethylornithine administered in combination are more effective in inhibiting chemically induced colon adenocarcinomas in male F 344 rats than are high doses of these agents given individually.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16168238     DOI: 10.1007/s11894-005-0009-x

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  50 in total

Review 1.  Omega-3 fatty acids in colorectal cancer prevention.

Authors:  Bandaru S Reddy
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

2.  Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention.

Authors:  J L Williams; S Borgo; I Hasan; E Castillo; F Traganos; B Rigas
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

3.  Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac.

Authors:  B Agarwal; C V Rao; S Bhendwal; W R Ramey; H Shirin; B S Reddy; P R Holt
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

4.  Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study.

Authors:  G A Kune; S Kune; L F Watson
Journal:  Cancer Res       Date:  1988-08-01       Impact factor: 12.701

5.  Sulindac in familial adenomatous polyposis.

Authors:  F Tonelli; R Valanzano
Journal:  Lancet       Date:  1993-10-30       Impact factor: 79.321

6.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

7.  Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis.

Authors:  C H Chiu; M F McEntee; J Whelan
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

8.  Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens.

Authors:  Malisetty V Swamy; Indranie Cooma; Bandaru S Reddy; Chinthalapally V Rao
Journal:  Int J Oncol       Date:  2002-04       Impact factor: 5.650

9.  Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer.

Authors:  T Kawamori; R Lubet; V E Steele; G J Kelloff; R B Kaskey; C V Rao; B S Reddy
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

10.  Effect of sulindac on sporadic colonic polyps.

Authors:  J Ladenheim; G Garcia; D Titzer; H Herzenberg; P Lavori; R Edson; M B Omary
Journal:  Gastroenterology       Date:  1995-04       Impact factor: 22.682

View more
  3 in total

1.  Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats.

Authors:  Chinthalapally V Rao; Vernon E Steele; Malisetty V Swamy; Jagan M R Patlolla; Suresh Guruswamy; Levy Kopelovich
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

2.  Reversibility of aberrant global DNA and estrogen receptor-alpha gene methylation distinguishes colorectal precancer from cancer.

Authors:  Rulong Shen; Lianhui Tao; Yiqing Xu; Shi Chang; James Van Brocklyn; Jian-Xin Gao
Journal:  Int J Clin Exp Pathol       Date:  2008-04-20

3.  Colorectal carcinogenesis: Review of human and experimental animal studies.

Authors:  Takuji Tanaka
Journal:  J Carcinog       Date:  2009
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.